McDermott Will & Schulte, a global law firm

Emmanuelle Trombe is the co-head of the Firm’s Life Sciences industry practice. She represents pharmaceutical, medical device and bio-pharmaceutical companies globally in transactional matters in relation to M&A and divestitures, joint ventures and strategic partnerships, large-scale projects, outsourcing projects, product development, licensing agreements and regulatory matters. She also advises venture capital funds and bio-pharmaceutical companies in connection with a broad range of financing activities. As well as co-heading the Firm’s Life Sciences Group, Emmanuelle serves as an elected member of the Firm’s Management Committee.

Emmanuelle is distinguished in Chambers Europe and Legal 500 EMEA in life sciences transactions, where she is highly recommended for her experience in the pharmaceutical, healthcare, biotech and medical devices industries and described as very responsive, smart, flexible and business-minded. She has been distinguished as the Lawyer of the Year in Life Sciences for 2024.

Andrew J. Warmus focuses his practice on domestic and cross-border mergers and acquisitions, joint ventures, and other strategic transactional matters. He has broad experience representing private equity firms and other financial sponsors, multinational public companies, private companies, and founders in material and transformative transactions across multiple industries, with significant experience in the life sciences sector, including pharmaceuticals, diagnostics, and medical devices.

Andrew advises buyers and sellers in acquisitions, divestitures, and strategic transactions often involving complex, multijurisdictional carve-out transactions in regulated industries. He also provides counsel to several portfolio companies on a wide range of matters and builds and leads bespoke teams to deliver commercial solutions.

Andrew is a member of the Firm’s Cross-Border Steering Committee.